These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 23129424)

  • 1. Midkine is associated with neuroendocrine differentiation in castration-resistant prostate cancer.
    Nordin A; Wang W; Welén K; Damber JE
    Prostate; 2013 May; 73(6):657-67. PubMed ID: 23129424
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Elevated circulating tissue inhibitor of metalloproteinase 1 (TIMP-1) levels are associated with neuroendocrine differentiation in castration resistant prostate cancer.
    Gong Y; Chippada-Venkata UD; Galsky MD; Huang J; Oh WK
    Prostate; 2015 May; 75(6):616-27. PubMed ID: 25560638
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stem-like cells with luminal progenitor phenotype survive castration in human prostate cancer.
    Germann M; Wetterwald A; Guzmán-Ramirez N; van der Pluijm G; Culig Z; Cecchini MG; Williams ED; Thalmann GN
    Stem Cells; 2012 Jun; 30(6):1076-86. PubMed ID: 22438320
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neuroendocrine differentiation in hormone refractory prostate cancer following androgen deprivation therapy.
    Hirano D; Okada Y; Minei S; Takimoto Y; Nemoto N
    Eur Urol; 2004 May; 45(5):586-92; discussion 592. PubMed ID: 15082200
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The prognostic role of immunohistochemical chromogranin a expression in prostate cancer patients is significantly modified by androgen-deprivation therapy.
    Berruti A; Bollito E; Cracco CM; Volante M; Ciccone G; Porpiglia F; Papotti M; Scarpa RM; Dogliotti L
    Prostate; 2010 May; 70(7):718-26. PubMed ID: 20087896
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunohistochemical and ultrastructural features of neuroendocrine differentiated carcinomas of the prostate: an immunoelectron microscopic study.
    Hirano D; Jike T; Okada Y; Minei S; Sugimoto S; Yamaguchi K; Yoshikawa T; Hachiya T; Yoshida T; Takimoto Y
    Ultrastruct Pathol; 2005; 29(5):367-75. PubMed ID: 16257863
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neuroendocrine differentiation in prostate carcinoma: focusing on its pathophysiologic mechanisms and pathological features.
    Alberti C
    G Chir; 2010; 31(11-12):568-74. PubMed ID: 21232206
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of abiraterone acetate on circulating neuromediators in chemotherapy-naïve castration-resistant prostate cancer.
    von Hardenberg J; Schwartz M; Werner T; Fuxius S; Müller M; Bolenz C; Weiß C; Heinrich E
    Prostate; 2016 May; 76(7):613-9. PubMed ID: 26779767
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neuroendocrine differentiation in castration-resistant prostate cancer: a systematic diagnostic attempt.
    Matei DV; Renne G; Pimentel M; Sandri MT; Zorzino L; Botteri E; De Cicco C; Musi G; Brescia A; Mazzoleni F; Tringali V; Detti S; de Cobelli O
    Clin Genitourin Cancer; 2012 Sep; 10(3):164-73. PubMed ID: 22401754
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Androgen deprivation of the PC-310 [correction of prohormone convertase-310] human prostate cancer model system induces neuroendocrine differentiation.
    Jongsma J; Oomen MH; Noordzij MA; Van Weerden WM; Martens GJ; van der Kwast TH; Schröder FH; van Steenbrugge GJ
    Cancer Res; 2000 Feb; 60(3):741-8. PubMed ID: 10676662
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Relationship of neuroendocrine differentiation to biological behavior of prostate cancer].
    Wu XL; Huang KT; Chen W; Chen L; Dong L; Yu ZX
    Zhonghua Yi Xue Za Zhi; 2009 Feb; 89(7):472-5. PubMed ID: 19567097
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neuroendocrine differentiation in the progression of prostate cancer.
    Komiya A; Suzuki H; Imamoto T; Kamiya N; Nihei N; Naya Y; Ichikawa T; Fuse H
    Int J Urol; 2009 Jan; 16(1):37-44. PubMed ID: 19120524
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The impact of diet and micronutrient supplements on the expression of neuroendocrine markers in murine Lady transgenic prostate.
    Palmer J; Venkateswaran V; Fleshner NE; Klotz LH; Cox ME
    Prostate; 2008 Mar; 68(4):345-53. PubMed ID: 18188867
    [TBL] [Abstract][Full Text] [Related]  

  • 14. N-cadherin increases after androgen deprivation and is associated with metastasis in prostate cancer.
    Jennbacken K; Tesan T; Wang W; Gustavsson H; Damber JE; Welén K
    Endocr Relat Cancer; 2010 Jun; 17(2):469-79. PubMed ID: 20233707
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neuroendocrine differentiation in prostate cancer: current and emerging therapy strategies.
    Conteduca V; Aieta M; Amadori D; De Giorgi U
    Crit Rev Oncol Hematol; 2014 Oct; 92(1):11-24. PubMed ID: 24952997
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prospective study on the relationship between clinical efficacy of secondary hormone therapy with flutamide and neuroendocrine differentiation in patients with relapsed prostate cancer after first line hormone therapy.
    Hirano D; Hasegawa R; Satoh K; Mochida J; Yamanaka Y; Hirakata H; Yamaguchi K; Sugimoto S; Kawata N; Takahashi S
    Scand J Urol; 2014 Oct; 48(5):436-44. PubMed ID: 24730473
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New perspective in the management of neuroendocrine differentiation in prostate adenocarcinoma.
    Sciarra A; Cardi A; Dattilo C; Mariotti G; Di Monaco F; Di Silverio F
    Int J Clin Pract; 2006 Apr; 60(4):462-70. PubMed ID: 16620361
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic significance of proliferation activity and neuroendocrine differentiation to predict treatment failure after radical prostatectomy.
    May M; Siegsmund M; Hammermann F; Loy V; Gunia S
    Scand J Urol Nephrol; 2007; 41(5):375-81. PubMed ID: 17853019
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Zoledronic acid but not somatostatin analogs exerts anti-tumor effects in a model of murine prostatic neuroendocrine carcinoma of the development of castration-resistant prostate cancer.
    Hashimoto K; Masumori N; Tanaka T; Maeda T; Kobayashi K; Kitamura H; Hirata K; Tsukamoto T
    Prostate; 2013 Apr; 73(5):500-11. PubMed ID: 22996996
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Secretagogin is a new neuroendocrine marker in the human prostate.
    Adolf K; Wagner L; Bergh A; Stattin P; Ottosen P; Borre M; Birkenkamp-Demtröder K; Orntoft TF; Tørring N
    Prostate; 2007 Apr; 67(5):472-84. PubMed ID: 17285592
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.